TI
ABBV icon

Truepoint Inc’s AbbVie ABBV Stock Holding History

Truepoint Inc’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Buy
1,363
+74
+6% +$15.9K 0.01% 126
2026
Q1 		$280K Buy
1,289
+155
+14% +$34.4K 0.01% 132
2025
Q4 		$259K Sell
1,134
-548
-33% -$125K 0.01% 133
2025
Q3 		$389K Hold
1,682
– – 0.01% 111
2025
Q2 		$312K Buy
1,682
+16
+1% +$2.97K 0.01% 117
2025
Q1 		$349K Sell
1,666
-223
-12% -$43.4K 0.01% 109
2024
Q4 		$336K Sell
1,889
-367
-16% -$67.5K 0.01% 104
2024
Q3 		$446K Buy
2,256
+573
+34% +$107K 0.01% 97
2024
Q2 		$289K Sell
1,683
-68
-4% -$11.3K 0.01% 105
2024
Q1 		$319K Sell
1,751
-3,547
-67% -$611K 0.01% 104
2023
Q4 		$821K Sell
5,298
-811
-13% -$118K 0.02% 92
2023
Q3 		$911K Buy
6,109
+3,382
+124% +$496K 0.03% 82
2023
Q2 		$367K Buy
2,727
+938
+52% +$138K 0.01% 116
2023
Q1 		$285K Buy
1,789
+407
+29% +$62.2K 0.01% 119
2022
Q4 		$223K Sell
1,382
-1,017
-42% -$156K 0.01% 146
2022
Q3 		$322K Hold
2,399
– – 0.02% 115
2022
Q2 		$367K Buy
2,399
+1,000
+71% +$153K 0.02% 119
2022
Q1 		$227K Buy
+1,399
New +$203K 0.01% 130
2021
Q4 		– Sell
-6,499
Closed -$701K – 136
2021
Q3 		$701K Buy
6,499
+4,714
+264% +$539K 0.04% 68
2021
Q2 		$201K Buy
+1,785
New +$201K 0.01% 118
2020
Q1 		– Sell
-2,428
Closed -$215K – 48
2019
Q4 		$215K Buy
+2,428
New +$202K 0.02% 112
2019
Q2 		– Sell
-2,496
Closed -$201K – 122
2019
Q1 		$201K Buy
+2,496
New +$204K 0.02% 107

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Truepoint Inc's ABBV Position: Q2 2026 in Review

Truepoint Inc increased its AbbVie (ABBV) stake by 5.7% in Q2 2026, buying an estimated $15.9K and bringing the position to 1,363 shares worth $343K. The position accounts for 0.01% of the portfolio, ranked #126.

Truepoint Inc first reported a position in ABBV in Q1 2019 and has held it in 22 quarters since. The position peaked at $911K in Q3 2023. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Truepoint Inc held 1,363 shares of AbbVie worth $343K as of Q2 2026.
  • Truepoint Inc bought 74 AbbVie shares in Q2 2026, an estimated $15.9K.
  • AbbVie made up 0.01% of Truepoint Inc's portfolio in Q2 2026, its #126 holding.
  • Truepoint Inc first reported a position in AbbVie in Q1 2019 and has held it in 22 quarters since.
  • Truepoint Inc's AbbVie position peaked at $911K in Q3 2023.
  • 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Truepoint Inc's 13F filing for Q2 2026, filed 31 Jul 2026.